Pelvic Floor and Sexual Dysfunction in Women with Sjogren's Syndrome
Investigation of the Relationship Between the Pelvic Floor and Sexual Dysfunction in Women with Sjogren's Syndrome
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Antalya, Turkey, 07059
- Ayse Ayan
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- being between the ages of 18-65
- being a woman,
- having sex partner,
- no smoking, no alcohol
Exclusion Criteria:
- physical, psychological, cognitive impairment,
- having a non-Sjögren additional disease,
- malignancy,
- pregnancy,
- no urogenital disease,
- sarcoidosis,
- AIDS,
- anticholinergic drug use,
- had a gynecological or urological operation other than cesarean
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Group
Women with diagnosed Sjogren syndrome
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pelvic Floor Distress Inventory PFDI-20
Time Frame: 1 week
|
Pelvic Floor Distress Inventory has a total of 20 questions and 3 scales (Urinary Distress Inventory, Pelvic Organ Prolapse Distress Inventory, and Colorectal-Anal Distress Inventory).
Each short-form scale demonstrates significant correlation with their long-form scales
|
1 week
|
|
Pelvic Floor Impact Questionnaire PFIQ
Time Frame: 1 week
|
Pelvic Floor Impact Questionnaire (PFIQ): The questionnaire has 7 questions and each question has 3 separate responses.
The response to each item of satisfaction, impact and worry was rated from 3 (quite a bit) to 0 (not at all) for the PFIQ-7.
The mean value for all the answered items within the corresponding scale (possible value 0-3) was estimated, then multiplied by (100/3) to obtain the scale score, range 0-100.
|
1 week
|
|
Female Sexual Dysfunction Index FSFI
Time Frame: 1 week
|
The FSFI is a brief questionnaire measure of sexual functioning in women.
It was developed for the specific purpose of assessing domains of sexual functioning (e.g.
sexual arousal, orgasm, satisfaction, pain) in clinical trials.
|
1 week
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Ayse Ayan, University of Health Sciences Antalya Training and Research Hospital
Publications and helpful links
General Publications
- van Nimwegen JF, Arends S, van Zuiden GS, Vissink A, Kroese FG, Bootsma H. The impact of primary Sjogren's syndrome on female sexual function. Rheumatology (Oxford). 2015 Jul;54(7):1286-93. doi: 10.1093/rheumatology/keu522. Epub 2015 Feb 4.
- Budden AK, Te West NI, Sturgess AD, Moore KH. Pelvic floor dysfunction in female Sjogren's syndrome: an 8-year audit. Int Urogynecol J. 2016 Sep;27(9):1367-73. doi: 10.1007/s00192-016-2985-9. Epub 2016 Mar 10.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urogenital Diseases
- Musculoskeletal Diseases
- Mouth Diseases
- Stomatognathic Diseases
- Male Urogenital Diseases
- Pathological Conditions, Anatomical
- Urologic Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Arthritis
- Joint Diseases
- Rheumatic Diseases
- Signs and Symptoms, Digestive
- Connective Tissue Diseases
- Autoimmune Diseases
- Immune System Diseases
- Pregnancy Complications
- Urination Disorders
- Lower Urinary Tract Symptoms
- Urological Manifestations
- Eye Diseases
- Arthritis, Rheumatoid
- Xerostomia
- Salivary Gland Diseases
- Dry Eye Syndromes
- Lacrimal Apparatus Diseases
- Urinary Incontinence
- Sjogren's Syndrome
- Constipation
- Prolapse
- Pelvic Organ Prolapse
- Pelvic Floor Disorders
Other Study ID Numbers
Other Study ID Numbers
- 2019-166
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Urinary Incontinence
-
NCT02418299CompletedFemale Stress Urinary Incontinence | Mixed Incontinence, Urge and Stress
-
NCT03672461CompletedUrinary Incontinence, Stress | Urge Incontinence | Urinary Stress Incontinence | Stress Incontinence, Urinary | Stress Incontinence | Stress Incontinence, Female | Urgency Urinary
-
NCT01227447UnknownIncontinence, Overactive Bladder, Stress Urinary Incontinence
-
NCT03877640RecruitingStress Urinary Incontinence | Urge Incontinence
-
NCT01366066TerminatedStress Urinary Incontinence | Urge Urinary Incontinence
-
NCT05677295RecruitingWomen With Stress Urinary Incontinence
-
NCT03180372CompletedUrinary Incontinence | Stress Urinary Incontinence | Urge Incontinence
-
NCT05464316RecruitingUrinary Incontinence | Urinary Stress Incontinence | Post-Prostatectomy Incontinence | Stress Incontinence, Male
-
NCT01445834CompletedStress Urinary Incontinence | Urge Urinary Incontinence
-
NCT00197314CompletedUrinary Stress Incontinence (SI)